Sign up for the QMED & MD+DI Daily newsletter.
Allurion Files for PMA Submission of Elipse Gastric Balloon
The Natick, MA-based company has also hired a VP of Regulatory Affairs and Quality Assurance to help it in its bid to get the weight-loss device to the market. The measure comes hot on the heels of Allurion raising $34 million in new funding.
April 7, 2020
2 Min Read
Allurion Technologies is one step closer to having its Elipse gastric balloon enter the U.S. market. The Natick, MA-based company announced the PMA submission of the device early Tuesday.
The submission comes hot on the heels of Allurion raising $34 million in new funding through a securities financing and a growth capital term loan. Allurion also announced the hiring of Joyce Johnson as VP, Regulatory Affairs and Quality Assurance.
“Joyce comes to Allurion at an opportune and exciting time as we work towards receiving US regulatory approval from the FDA for the Elipse Balloon,” said Shantanu Gaur, M.D., co-founder and Chief Executive Officer of Allurion. “Her track record of success and leadership in the areas of compliance and quality assurance will prove valuable as we continue to rapidly scale the business.”
The company said unlike other weight loss balloons on the market, the Elipse Balloon is designed to be placed and removed without surgery, endoscopy, or anesthesia. It is swallowed in a capsule during an outpatient office visit and is designed to remain in the stomach for about four months, after which it opens and passes naturally from the body.
Elipse could be available in the U.S. market in late 2020, the company said in a release.
While Allurion is making progress, Obalon Therapeutics, one of its competitors, is exploring strategic options because of the negative impact of the coronavirus (COVID-19) on elective procedures.
Late last month, the weight loss specialist said these alternatives could include equity or debt financing; a sale of the company; a business combination; or a merger or a reverse merger with another party.
Obalon has developed a gas-filled intragastric balloon system that treats obesity. The device won a nod from FDA back in 2016. A little more than a year ago, the company released its direct sales force and began marketing the device through special centers.
About the Author(s)
You May Also Like
Pedersen's POV graphic featuring the headshot of MD+DI Senior Editor Amanda Pedersen and a pull quote from the latest edition of her opinion column.
BioSig's Ridiculously Sparse Layoff Announcement Reeks of CallousnessFeb 26, 2024|3 Min Read
Your Smartwatch Can’t Measure Blood Glucose Levels… YetFeb 26, 2024|3 Min Read
Medtech in a Minute: Medtronic Pulls the Plug on Ventilators and MoreFeb 26, 2024|1 Min Read
The Good, The Bad, and The Ugly in Medtech DealsFeb 23, 2024|9 Slides